We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Neoleukin Therapeutics, Inc's financial performance into perspective.
February 5, 2021
January 8, 2021
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
January 7, 2021
March 12, 2021 at 3:00 PM EST
January 14, 2021 at 4:30 PM EST